Intravenou Bevacizumab Caue Regreion of Choroidal Neovacularization econdary to Dieae Other Than Age-related Macular Degeneration Original Reearch Article

Purpoe To invetigate the afety, tolerability, and bioactivity of intravenou infuion of bevacizumab in patient with choroidal neovacularization (CNV) attributable to caue other than age-related macular degeneration. Deign Nonrandomized clinical trial. Method Ten patient with CNV received infuion of 5 mg/kg of bevacizumab. The primary efficacy outcome meaure wa change in viual acuity (VA; Early Treatment Diabetic Retinopathy tudy letter read at 4 meter) at 24 week and econdary meaure were change from baeline in exce foveal thickne (center ubfield thickne), area of fluorecein leakage, and area of CNV. Reult Infuion were well tolerated and there were no ocular or ytemic advere event. At baeline, median VA wa 25.5 letter read at 4 meter (20/80) and median foveal thickne wa 346 μm. At the primary endpoint (24 week), median VA wa 48.5 letter (20/32), repreenting four line of improvement from baeline (P = .005), median foveal thickne wa 248 μm repreenting a 72% reduction in exce foveal thickne (P = .007). Four of nine patient had complete elimination of fluorecein leakage, three had near complete elimination (reduction of 91%, 88%, and 87%), two had modet reduction, and one had no reduction. All patient except one howed a reduction in area of CNV with a median reduction of 43%. Concluion Depite the mall number of patient tudied, the marked improvement in VA accompanied by prominent reduction in foveal thickne, fluorecein leakage, and area of CNV ugget a beneficial effect. It may be worthwhile to conider further evaluation of ytemic bevacizumab in young patient with CNV.